Traditional Therapy Profiles · Formulation

Gokshuradi Guggulu

Also called: Gokshuradi Guggul, Gokshuradi Gulgulu

Many ingredients: gokshura · guggulu · triphala · trikatu

One tablet. Different clinical intentions.

New here? How to read these profiles

The important distinction

Gokshuradi Guggulu is prescribed where sugar and urine conversations meet. Families often leave unsure which problem the tablet was mainly meant to address. That intention matters more than the shared name.

What it is

A classical Ayurvedic guggulu vati centered on gokshura (Tribulus terrestris) with guggulu, triphala, trikatu, and supporting herbs in traditional recipes.

Clinicians reach for it where sugar and urine conversations meet. The same tablet may be prescribed for different primary problems.

Where you will encounter it

  • Practitioner visits where sugar control and urinary complaints come up in the same conversation
  • Patients who say their doctor added a "guggulu for urine" after starting diabetes medicines
  • Ayurvedic metabolic bags alongside Nishamalaki or Chandraprabha Vati
  • OTC labels that borrow the classical name for combined glucose and kidney support

Further detail

Clinical intention

The same tablet can sit at the crossroads of metabolism and urinary care.

Classical practice places this vati where those conversations meet. That is why one prescription can legitimately target glucose, urine symptoms, or kidney markers. Unless you know which intention your practitioner was targeting, you cannot interpret the tablet.

What human research has studied

Trials follow one intention at a time.

Open-label work has tested glucose markers and diabetes symptom scores. Other protocols look at creatinine, albuminuria, or microalbuminuria, often with co-formulations. Each study answers one clinical intention.

A result for one intention does not license every other reason the tablet gets recommended.

What the evidence does not justify
  • Assuming one prescription intention covers sugar, urine, and kidneys at once
  • Treating a glucose study as kidney protection proof, or an albuminuria signal as glucose proof
  • Transferring guggulu resin lipid trials to this herb set
  • Replacing nephrology workups because a classical name spans kidney discourse
Questions worth asking

The useful first question is rarely "Does it cover sugar and urine?" It is "Why was I given this?"

  • Prescribed mainly for glucose, urine symptoms, or kidney markers?
  • What other herbs or vatis are in the same regimen?
  • Recent HbA1c, urine albumin, and creatinine values?
  • Which diabetes and blood pressure medicines are you already taking?
Safety and interaction attention

The review changes depending on whether glucose lowering or kidney disease is the dominant concern.

Additive glucose lowering with sulfonylureas, insulin, or other herbal metabolic products is plausible when glucose is the intention. Kidney disease changes risk calculus when kidney markers are the intention. Pregnancy and surgery contexts need explicit review either way.

Related entries

Names patients hear when sugar and urine come up together. Intention still has to be named.

  1. Chandraprabha Vati Formulation Another tablet in sugar-and-urine conversations. Different recipe, same overlapping speech.
  2. Guggulu Ingredient The naming stem. Resin trials are not this urinary-metabolic vati.
  3. Metabolic blend-type Product pattern OTC glucose stacks. Overlap marketing without classical formulation proof.

Commonly confused with

  • Mahayogaraja Guggulu (joint-pain vati with the same guggulu stem)
  • Gokshura or tribulus supplements sold without the classical vati name
  • Proprietary kidney or Cystone-type products without a classical formula name
Sources
  1. Srikanth N, et al. Evaluation of Gokshuradi Guggulu and Guduchi Churna in the management of type II diabetes mellitus (Madhumeha). J Res Ayurvedic Sci. 2019. doi:10.5005/jras-10064-0082
  2. Manwar SJ, et al. Effect of Ayurvedic management in 130 patients of diabetic nephropathy. Ayu. 2011. doi:10.4103/0974-8520.85727
  3. Anonymous. Management of microalbuminuria in stage 2 diabetic nephropathy: a case report. J Ayurveda Case Rep. 2020. doi:10.4103/JACR.JACR_16_20

Evidence blocks last reviewed: July 2026.

← Back to Traditional Therapy Profiles